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Abstract
Background: ADHD (attention deficit hyperactivity disorder) is a common neurodevelopmental disorder. There has
been extensive clinical and basic research in the field of ADHD over the past 20 years, but the mechanisms underlying
ADHD risk are multifactorial, complex and heterogeneous and, as yet, are poorly defined. In this review, we argue that
one approach to address this challenge is to study well-defined disorders to provide insights into potential biological
pathways that may be involved in idiopathic ADHD.
Main body: To address this premise, we selected two neurogenetic conditions that are associated with significantly
increased ADHD risk: Turner syndrome and the RASopathies (of which Noonan syndrome and neurofibromatosis type
1 are the best-defined with regard to ADHD-related phenotypes). These syndromes were chosen for two main reasons:
first, because intellectual functioning is relatively preserved, and second, because they are strikingly phenotypically
similar but are etiologically distinct. We review the cognitive, behavioural, neural and cellular phenotypes associated
with these conditions and examine their relevance as a model for idiopathic ADHD.
Conclusion: We conclude by discussing current and future opportunities in the clinical and basic research of these
conditions, which, in turn, may shed light upon the biological pathways underlying idiopathic ADHD.
Keywords: Attention deficit hyperactivity disorder, Neurofibromatosis type 1, Noonan syndrome, RASopathies, Turner
syndrome, X chromosome
Background
ADHD (attention deficit hyperactivity disorder, also
known as hyperkinetic disorder) is currently defined in
diagnostic manuals such as DSM-5 [1] and ICD-10 [2]
by a collection of persistent and impairing cognitive and
behavioural symptoms, notably inattention, hyperactivity
and pathological impulsivity. ADHD is the most com-
mon neurodevelopmental disorder in the USA, affecting
up to 10% of children and exhibiting a pronounced
male-biased diagnostic prevalence [3]. The biological
and environmental mechanisms underlying ADHD risk
are multifactorial, complex and heterogeneous [4, 5]
and, as yet, are poorly defined. There is accumulating
evidence that ADHD is associated with structural and
functional abnormalities across multiple brain circuits,
notably reduced volume of the basal ganglia, thinning of
the frontal and parietal cortex, and functional connecti-
vity between these regions [6]. In the absence of an
established pathophysiology, we are limited to using
treatments that target symptoms rather than core cellu-
lar and molecular abnormalities; as a result, the efficacy
and side-effect profile of these therapies is sub-optimal
and treatments cannot directly influence the course of
the disorder.
Identifying and characterising the many dysfunctional
biological pathways that culminate in the development
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of ADHD is a difficult, perhaps intractable, problem. On
the one hand, studying children and adults with idio-
pathic ADHD is hindered by limited sample sizes and
other issues that stem from within-group heterogeneity.
On the other hand, it is difficult to model the complex
cognitive and behavioural abnormalities seen in indivi-
duals with ADHD in animal models where experimental
control is more feasible. The study of well-defined neu-
rogenetic conditions in man circumvents, to some ex-
tent, challenges associated with etiological heterogeneity,
whilst allowing the measurement of complex human
behaviours in children and adult with these conditions.
In this review, we examine the premise that human neu-
rogenetic conditions that are associated with increased
ADHD rates may help to provide converging evidence for
biological pathways involved in the development of idio-
pathic ADHD. Specifically, we compare two phenotypi-
cally similar classes of human genetic conditions that may
serve as such ‘experimental models’: Turner syndrome
(TS) and the RASopathies. Of the known RASopathies,
we focus on Noonan syndrome (NS) and neurofibroma-
tosis type 1 (NF-1), conditions about which most data has
been collated in the literature. Moreover, whilst ADHD
symptomatology is reported across all of the RASopathies,
including Costello syndrome, LEOPARD syndrome, and
cardiofaciocutaneous syndrome (CFC), these disorders are
associated with pervasive effects on global cognitive func-
tion that might confound more specific genetic effects on
ADHD-related symptoms [7]. TS, NF1 and Noonan syn-
drome are mechanistically distinct conditions which result
in phenotypically aberrant behaviours and cognitive pro-
cesses, but individuals affected by these conditions have
similar overall cognitive profiles which lie within the nor-
mal range (Table 1). Importantly, the two classes of condi-
tion show striking overlap with regard to their associated
anatomical/physiological phenotypes (Table 1) and, as
such, there may feasibly be some degree of convergence
across both with respect to the biological mechanisms
underlying ADHD risk; clarifying the level at which the
genetically distinct aetiologies in TS and the RASopathies
might ultimately impact upon common brain substrates
underlying ADHD-related phenotypes (e.g. molecular, cel-
lular or brain circuit) will comprise an important avenue
for future research. We start by critically reviewing the
existing clinical and animal model literature relating to
cognitive, behavioural, neural and cellular phenotypes in
these conditions (Fig. 1) and examine their relevance as a
model for idiopathic ADHD.
ADHD-related behavioural and cognitive
phenotypes in TS, NF1 and NS
Significantly increased (~18-fold) rates of ADHD have
been reported in TS (~24%) relative to the general fe-
male population (1.3%) [8] whilst substantially elevated
rates of ADHD have also been reported in several of the
RASopathies, including NF1 and NS, relative to the ge-
neral population [9, 10]. For example, it has been re-
ported that in children with NF1, 38–49% meet
diagnostic criteria for ADHD, whilst an even larger pro-
portion experience considerable difficulties with sus-
tained attention [9, 11]. Children with NF1 also exhibit
high rates of explicit autism spectrum disorder (~25% of
cases) and autistic symptoms (~50% of cases), but these
diagnoses appear dissociable from ADHD-related beha-
viours [12]. ~31% of children with NS have been re-
ported to meet diagnostic criteria for ADHD [10]. It
should be acknowledged that there may be an over-
estimation of psychological issues in TS, NF1 and NS
populations arising from an ascertainment bias whereby
individuals with neurogenetic conditions are monitored
and assessed disproportionately deeply compared to
members of the general population.
The presentation of ADHD-related symptoms can vary
between TS, NF1 and NS. Girls with TS and ADHD
present with pronounced hyperactivity (comparable to
levels seen in idiopathic ADHD in boys) [13] and are
more likely to be diagnosed with the hyperactive-
impulsive presentation of the disorder [8]. Attention and
executive function deficits are, however, also apparent in
this population, and appear to be independent of other
cognitive deficits characteristic of this population such
as visuospatial impairment and general cognitive ability;
interestingly, there appears to be a bimodal distribution
within the TS group with regard to one measure of at-
tentional function [10]. In NF1 and NS, the primary
ADHD-related symptoms appear to be difficulties with
attention. In both groups, parental reports indicate that
children have clinically significant difficulties with self-
monitoring (36.5% children with NF1 and 38% of
children with NS) and planning-organisation (42.9%
children with NF1 and 38% with NS) [10, 14]. Direct
neuropsychological measures of ADHD-related beha-
viours also indicate that both children with NF1 and NS
experience significant difficulties with sustained atten-
tion and inhibition. However, obtaining accurate mea-
sures of ADHD-related behaviours in the RASopathies is
difficult; in some studies, assessments of children with
severe ADHD were excluded due to concerns regarding
their validity [10], and there is some degree of hetero-
geneity within the clinical population and in terms of
the assessment measures used (and the reporting of as-
sociated results).
An important question regarding ADHD-related phe-
notypes in these syndromes is whether they are the cul-
mination of relatively discrete disruption to molecular,
cellular and neural pathways, or whether they are simply
a subset of the many adverse neurobehavioural conse-
quences arising from gross brain maldevelopment; the
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fact that IQ is generally preserved across all three condi-
tions indicates the former. Overall therefore, TS, NF1
and NS might be regarded as behavioural models of spe-
cific subtypes, or symptoms, of ADHD in the absence of
general cognitive impairments. Currently, there is little
clinical and neuropsychological information available
that may indicate areas of commonality and difference
across the three syndromes, and there is undoubtedly a
need for further research in this area. Parallel in vivo
and in vitro studies such as neuroimaging and animal/
cellular model work may enable us to understand how
similarities and differences in neuroanatomy, neuro-
physiology and neurochemistry across the three syn-
dromes can contribute towards commonalities and
dissociations in behavioural and cognitive phenotypes.
Brain phenotype in TS, NF1 and NS: clinical and
animal model evidence
In TS, although total brain volume appears comparable
to that of healthy controls, there is evidence for de-
creased volumes of the cortex (particularly in parietal
and occipital regions), hippocampus, thalamus and basal
ganglia [15, 16]. The structure of the parietal lobe [16–18]
and its connectivity with other cortical regions (notably
the frontal cortex) [19, 20] appear to differ between
individuals with TS and controls. In addition, task-based
[21–23] and resting-state [24] functional connectivity
measures between the frontal and parietal cortex are re-
duced in girls with TS. Together, these data provide a pos-
sible neural mechanism underlying attention problems
and hyperactivity in TS.
Ongoing studies in mouse models with varying sex
chromosomal complements are attempting to refine the
brain sites that are most sensitive to X and Y chromosome
Fig. 1 Human disease model as a framework for the study of ADHD.
This framework theoretically models complex human behaviour not
available through mouse models for relatively genetically homogeneous
populations compared to the study of heterogenic populations
with ADHD. The structure of the current review is provided on
the Y axis, including the cognitive, behavioural, neural and cellular
phenotypes associated with Turner syndrome, Noonan syndrome,
and neurofibromatosis type 1
Table 1 The genetic mutations, protein products, clinical features, and general intellectual functioning associated with TS, NS
and NF1
Genetic mutation Protein Clinical phenotype General cognitive
functioning
Turner syndrome X chromosome
partial (mosaic)/
complete deletion
Reduced expression of
gene products encoded
by X-linked genes escaping
X-inactivation [121]
Renal/endocrine problems, cardiac defects,
short stature, webbed neck, eyelid ptosis,
increased inter-nipple distance [114, 116]
Mosaic/partial X
chromosome absence:
VIQ: 96.2 ± 15.9
PIQ: 79.5 ± 18.8
Complete X
chromosome absence:
VIQ: 106.4 ± 14.4
PIQ: 82.1 ± 15.9
[48]
Noonan syndrome - PTPN11 (50%) ⇒ ⇑ Shp2 tyrosine
phosphate enzyme
Short stature, webbed neck, eyelid ptosis,
increased inter-nipple distance, cardiac
defects, bleeding disorders [114, 115, 117, 118]
VIQ: 82.3 ± 20.0
PIQ: 87.1 ± 23.0
(May vary depending
upon specific mutation
[119, 120])
- SOS1 (10–15%) ⇒ ⇑ “Son Of Sevenless 1” protein
- RAF1 (5–10%) ⇒ ⇑ Serine-threonine kinase
activating MEK1/MEK2
- KRAS (0–5%) ⇒
[111]
Missense mutation KRAS
Isoform B [118]
- Other rare
mutations
Neurofibromatosis
type 1
NF1 gene
microdeletion
(chromosome
17q11) [112]
⇓ Neurofibromin [113] Café-au-lait spots, intertriginous freckling,
Lisch nodules, neurofibromas, optic
pathway gliomas, distinctive bony
lesions [111-113]
VIQ: 91.9 ± 14.7
PIQ: 91.1 ± 12.8
[11]
VIQ verbal IQ, PIQ performance IQ)
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dosage and that may therefore play a role in sex-biased
cognitive constructs, including vulnerability to neurodeve-
lopmental disorders such as autism and ADHD; interest-
ingly, these appear to include systems previously
implicated in ADHD vulnerability including the forebrain
cholinergic system and cerebelo-pontine-thalamo-cortical
circuitry [25]. The X-monosomic 39,XO mouse model
[26] appears to recapitulate, to some extent, the parietal
cortex and striatal structural abnormalities reported in TS
[25]. However, it should be noted that the extrapolation of
any findings from this work to humans is limited by the
fact that there are far fewer X-escapees in the mouse
than in human, and the physiological consequences of
X-monosomy in the mouse are likely to be different,
and generally less severe, than in human [27].
At a structural level, the brains of subjects haploinsuf-
ficient for NF1 appear grossly normal, although hyperin-
tensities, possibly reflecting aberrant myelin formations,
are seen in patient MRI scans [28]. In the basal ganglia,
thalamus and brainstem of patients, such hyperintensi-
ties tend to resolve over time (possibly as a consequence
of improved efficiency within white matter tracts) and
this resolution appears to be related to cognitive im-
provements, indicating likely pathogenicity [29]. There is
some, albeit limited, evidence for aberrant brain struc-
ture and function in NF1, compared to controls. Indivi-
duals with NF1 may exhibit increased total grey [30] and
white [31] matter volume, larger hippocampal and palli-
dum volumes bilaterally [32], aberrant white matter
microstructure (as indexed by increased diffusivity) [33]
and abnormal functional connectivity between regions
underlying social and cognitive function [34], particu-
larly in the anterior-posterior axis [35]. Mouse models in
which NF1 is conditionally ablated in embryonic cere-
bellar progenitors or neonatal granule neuron progeni-
tors exhibit abnormal cerebellar layering and structure
[36], a finding which indicates a critical role for NF1 in
normal cerebellar development, and which suggests a
possible neural mechanism for some of the motor prob-
lems commonly seen in NF1.
The neurobiology of patients with NS has been studied
to a limited extent (often in the context of a predispo-
sition to cancer), and genotype-phenotype correlations
have rarely been reported. Brain structure in NS appears
grossly normal, but neurological abnormalities have been
reported in some cases. Chiari I malformations have
been noted in some cases of NS [37], whilst a boy with
NS and a mutation in RAF1 was reported to exhibit ex-
ternal hydrocephalus and abnormal cerebrovascular
pathology [38]. An adult female harbouring a KRAS mu-
tation followed over the course of several years displayed
epilepsy, and hippocampal sclerosis and atrophy [39];
neuroimaging and animal model work (see below) de-
monstrates that hippocampal pathology appears to be a
feature common to NF1 and other RASopathies. Individ-
uals with NS and a newly reported mutation in SHOC2 ex-
hibit a relative megalencephaly, enlarged subarachnoid
spaces, a relatively small posterior fossa, and a high rate of
cerebellar tonsillar ectopia [40].
Candidate molecular mechanisms underlying
increased rates of ADHD in TS
Neuropsychological differences between neurotypical
46,XX females and females with TS could potentially arise
due to one or more fundamental genetic mechanisms.
First, a plausible reason for increased ADHD rates in
TS stems from the fact that these individuals, like males,
are functionally hemizygous for some, or all, X-linked
genes. Hence, the effects of X-linked mutations or poly-
morphisms that elicit ADHD-related phenotypes will be
apparent, and will not be moderated by the effects of the
second X-linked allele. Candidate gene studies have pre-
viously implicated polymorphisms within the X-linked
MAOA and HTR2C genes in phenotypes associated with
ADHD [41, 42]; recent recognition that the X chromo-
some must also be incorporated in genomewide asso-
ciation studies together with the development of
statistical tools to perform such analyses (e.g. XWAS
[43]), is likely to drive the generation unbiased evidence
for association between multiple X-linked genetic va-
riants and ADHD-related phenotypes in the near future.
The second genetic mechanism that may explain why
ADHD rates are higher in TS than healthy control sub-
jects is X-linked gene dosage. The epigenetically me-
diated process of X-inactivation silences one of the two
X chromosomes within a female cell to ensure dosage
equivalence (and hence gross phenotypic equivalence) to
male cells where only one X chromosome is active [44].
However, this silencing process is not complete, and
~15–20% of human X-linked genes are thought to es-
cape X-inactivation to some extent, including both in
the pseudoautosomal regions and the X-specific portion
of the chromosome [45]; for this subset of genes, expres-
sion levels will be higher (though not necessarily double)
in female than male cells due to the fact that expression
proceeds from two X-linked alleles in females, but only
one in males. If reduced dosage for one or more of these
so-called ‘X-escapees’ confers ADHD risk, then we might
expect individuals with just one X-linked allele (i.e.
males and females with TS) to exhibit greater vulnerabi-
lity than 46,XX females. Work in animal models has
begun to identify X-escapees that might influence in-
creased ADHD risk in TS via gene dosage mechanisms
(see below). For TS subjects possessing one intact X
chromosome and a second X chromosome with a terminal
or interstitial chromosomal deletion, the second X
chromosome may be preferentially inactivated [46]; this
process may both skew the relative expression of X-linked
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alleles from the paternally and maternally inherited X chro-
mosomes, and subtly affect the expression of X-escapees.
The final genetic mechanism that may explain the ele-
vated ADHD rates in TS is the parental origin of the X
chromosome [47]. Briefly, there is limited, somewhat
contentious (e.g. [48]), evidence from human [46] and
mouse [49] studies that possessing a single maternally
inherited X chromosome (45,XM) results in poorer social
function, and a greater degree of behavioural inflexibi-
lity, than inheriting a single paternally inherited X
chromosome (45,XP). Neurotypical 46, XX females in-
herit one X chromosome from either parent, and there-
fore any deleterious effects of the maternally inherited X
chromosome may be compensated for by the presence
of the paternally inherited X chromosome. Impaired so-
cial function, aberrant behavioural inhibition and beha-
vioural inflexibility is commonly seen in individuals with
ADHD [50]. As a large proportion (~70%) of X-
monosomic women inherit their single X chromosome
maternally, we might expect the TS group as a whole to
be more severely affected with regard to these ADHD-
related brain and behavioural measures than 46,XX fe-
males. This ‘parent-of-origin’ idea is not supported by
data from the one, rather small, published study that has
explicitly tested whether rates of ADHD diagnoses in in-
dividuals with 45,XP and XM karyotypes differ (although
behavioural flexibility was not assayed in any depth) [8];
however, there is some evidence from TS that parent-of-
origin effects may influence aspects of cognition per-
turbed in ADHD [48, 51].
The genetic mechanisms above could potentially in-
fluence brain function directly. Alternatively, they could
exert effects on neurodevelopment and brain function
indirectly through affecting the development and func-
tion of other organs. TS is commonly associated with
impaired ovarian formation (and hence reduced levels of
systemic reproductive hormones); the condition is also
linked to abnormalities in levels of circulating growth
hormone and thyroid hormones [52]. An important
question is whether the ADHD-related symptoms and
cognitive deficits in TS, are influenced primarily by di-
rect genetic effects, primarily by indirect, hormonally
mediated effects, or by an equal contribution of the two
pathways. There are a number of lines of evidence which
suggest that the first option may be the most plausible.
For example, many TS cognitive deficits are maintained
throughout development despite considerable fluctua-
tions in levels of circulating hormones across the life-
course; moreover, cognitive deficits are not alleviated to
any significant extent by the administration of oestro-
gens, androgens or growth hormone (e.g. Freriks et al.,
2015 [53]), and women with premature ovarian failure
who exhibit similar hormonal profiles to women with TS
do not present with a similar constellation of cognitive
deficits [54]. However, some modulatory role for hor-
monal (and environmental) influences on cognition,
particularly during foetal development or early child-
hood, is likely.
Given the data above, which sex-linked genes may be
regarded as candidates for influencing attentional phe-
notypes in TS, and which neural circuitry may they in-
fluence? Y-linked genes that may be of particular
interest with respect to ADHD include the male-
determining gene SRY (which is expressed in dopami-
nergic neuron-rich brain regions and is duplicated in
cases of ADHD), and NLGN4Y and PCDH11Y, which
encode cell membrane molecules important in maintai-
ning synapse integrity and cell-cell interactions respec-
tively, and both of which have been implicated as
candidate genes for neurodevelopmental disorders [55].
In TS these mechanisms might come into play in indi-
viduals where mosaic Y-linked sequences inherited from
their father are present.
Deletion mapping strategies (whereby the phenotypes
of TS subjects possessing a variety of partial deletions
of the second X chromosome are assessed) have been
useful for identifying genomic regions that may poten-
tially underlie X-linked gene dosage effects on executive
function and social cognition. Zinn and colleagues have
shown that individuals in which a small portion of the
short of the X chromosome was missing (Xp22.3) con-
sistently demonstrate abnormal neurocognitive func-
tion, including across an assay of attention (TOVA) on
which subjects with ADHD are impaired [56]. Of the
31 genes within this interval, the authors suggested STS
and NLGN4X (the X-linked homologue of NLGN4X) as
candidate genes. STS escapes X-inactivation in both
humans and mouse [57] and consequently is more
highly expressed in foetal and adult female than male
brain (unpublished results). Recent cross-species
work has strengthened the evidence for this gene as
a mediator of attention. Specifically, X-monosomic
mice (which exhibit neither short stature nor gross
hormonal abnormalities) exhibit attentional deficits
that can be rescued by the presence of a small
chromosome housing Sts [58]; moreover, mice lac-
king the Sts gene, or mice in which the associated
steroid sulfatase enzyme is inhibited, show attentional
deficits and other phenotypes of relevance to ADHD
[42, 47, 59, 60]. In a demonstration of the power of
studying rare neurogenetic conditions to understand
the pathophysiology underlying more common idio-
pathic disorders, we, and others, have shown, on the
basis of work predicting steroid sulfatase involvement
in (in)attention from TS and related mouse models,
that polymorphisms within STS are associated with
the inattentive symptom count in boys diagnosed
with idiopathic ADHD [61, 62].
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Deletion mapping in TS has also revealed a small
dosage-sensitive locus at Xp11.3 that is linked to im-
paired emotion recognition and increased orbitofrontal
cortex grey matter and amygdala size [63]; follow-up
genetic association analyses have implicated a variant
within the EFHC2 gene in these phenotypes in both fe-
males with TS and healthy males [64, 65], although the
data from TS is somewhat controversial [66]. There is
some evidence that individuals with ADHD exhibit ab-
normal orbitofrontal cortex grey matter volumes, and
related deficits in emotion perception [67–70]; testing
for genetic association within EFHC2 and these pheno-
types within idiopathic ADHD therefore represents a
sensible future avenue for research. To date, no X-linked
genes whose expression is significantly influenced in a
parent-of-origin dependent manner have been identified
in human somatic tissues, including brain. Interestingly,
however, the closest human orthologue of the genomi-
cally imprinted maternally expressed mouse gene Xlr3b
identified in a mouse model of TS [49], FAM9B, is lo-
cated at Xp22.3 adjacent to the interval for TS neuro-
cognitive function indicated by deletion mapping. Whilst
FAM9B is apparently not expressed in the brain, it is
expressed in other reproductive tissues [71] and is asso-
ciated with levels of serum androgens in men [72]. In-
vestigating whether FAM9B activity may partially
explain the X-linked POE on behaviour seen in TS, and
assessing whether this gene may play a role in ADHD-
relevant phenotypes related to circulating androgens
[41] will also be a worthwhile avenue for further studies.
The bimodal peak in attention problems within a sam-
ple of participants with TS reported recently [13] is intri-
guing and could be explained in a number of ways. First,
the distinct sub-groups may have differed subtly in their
demographic characteristics (e.g. age, or socioeconomic
group) or with respect to their medication regimes, al-
though comparing the two subgroups on these measures
did not find significant differences (p > 0.5). Alterna-
tively, the two groups may have differed in this cognitive
domain as a function of their (epi)genotype. Theoreti-
cally, the bimodal distribution might have arisen due to
phenotypic differences between 45,XP and 45,XM sub-
jects, although, overall, and consistent with previous
data [8], the authors found no evidence for parent-of-
origin of the X chromosome influencing ADHD rates
within the TS sample. More plausibly, this particular
pattern of data may be most parsimoniously explained
by hemizygosity, with subjects possessing one or other
alleles of X-linked genes affecting attentional processes.
Given the converging evidence from human and mouse
studies for an attentional role for STS (and inherent ge-
netic polymorphisms) described above, we hypothesise
that the two groups may be distinguished by their geno-
type at this locus, or by systematic levels of metabolites
dependent upon enzyme function (e.g. dehydroepian-
drosterone, DHEA).
An alternative method to deletion mapping for identi-
fying candidate genes underlying ADHD-related pheno-
types in TS is to compare gene expression in case
samples with that of neurotypical controls. Comparing
tissue expression between the two groups is difficult for
a number of reasons including the unavailability of the
most pertinent tissue (i.e. brain), and obtaining TS sam-
ples from donors with consistent ages, karyotypes, hor-
monal profiles, and treatment histories. A comparison of
cell-free RNA levels from the amniotic fluid surrounding
TS or euploid female foetuses, which circumvents some
of the aforementioned problems, has hinted at dysregu-
lation of the hematologic/immune system in TS and has
highlighted a number of specific X-linked and autosomal
candidate genes for TS phenotypes [73]; of these, three
have previously been tentatively linked to idiopathic
ADHD by genetic association studies (FEN1/ELOVL6
[74], GSK3B [75] and BAIAP2 [76]) and as such may be
regarded as potential modulators of ADHD risk both
within TS and within the general population. A compari-
son of gene expression in induced pluripotent stem (iPS)
cells derived from individuals with TS or 46,XX indivi-
duals has revealed that X-monosomy results in extensive
effects on the whole transcriptome, with most impact
upon genes involved in central nervous system develop-
ment [77]; of the most highly differentially expressed
genes (>20-fold change), the two with the most rele-
vance to ADHD are DPP6 [78] and MYT1L [79]. Clearly,
gene expression differences in iPS cells may not provide
an accurate representation of gene expression differences
that occur in the developing and mature brains of TS
and 46,XX individuals, and, as such, future studies might
aim to compare the expression of differentiated neural
cells with a view to identifying more plausible candidates
for TS cognitive phenotypes.
Candidate cellular mechanisms underlying
increased rates of ADHD in RASopathies
Several converging lines of evidence have implicated
GABAergic dysfunction in NF1 cognitive pathology. A
seminal series of studies focussing on the hippocampus
showed that mice heterozygous for a null NF1 mutation ex-
hibited excessive Ras activity, enhanced ERK and synapsin I
phosphorylation and increased GABA-mediated inhibition,
and consequently specific deficits in long term potentiation
of potential relevance to learning deficits [80, 81]; the aber-
rant phenotypes could be partially rescued by administra-
tion of a GABA antagonist. More recent work has shown
that GABA-mediated inhibition in NF1-deficient mice may
influence working memory performance via effects on fron-
tostriatal circuitry, a result consistent with the observation
that NF1 patients exhibit hypoactivation of this system [82].
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Of particular relevance to this review, NF1-deficient
mice exhibit attentional impairments in a stimulus de-
tection task dependent upon prefrontal cortex function
[83]. The extent to which the attentional deficits seen in
these mice are a result of GABAergic dysfunction re-
mains to be formally tested e.g. via pharmacological ma-
nipulations. Consistent with the notion of a brain
region-specific GABAergic deficit influencing ADHD-
related phenotypes in NF1, work in humans has shown
that NF1 patients exhibit impaired impulse control, al-
terations in electroencephalographic (EEG) signatures of
basic sensory and visual processing [84], and reduced
GABA (but not glutamate) levels in the medial frontal
and occipital cortex [85]; only in the medial frontal cor-
tex were GABA levels correlated with impulse control,
and in the opposite direction in NF1 patients and con-
trols. Impairments in social cognitive function are fre-
quently seen in ADHD cases, as discussed above. Work
in heterozygous NF1 knockout mice in which the MAP
kinase pathway was over-activated in neurons of the
amygdala and frontal cortex, showed a selective social
learning deficit and disruption to GABA and glutamater-
gic neurotransmission [86]; this study further implicates
effects on excitatory and inhibitory neurotransmitter sys-
tems as being key to ADHD-related phenotypes in NF1.
Work in animal and cellular models have also shown
that disruption of the Ras signalling cascade has down-
stream effects on dopaminergic function that may par-
tially explain the cognitive deficits associated with NF1.
Most germane to the ‘attentional’ focus of this review, is
the observation that NF1-deficient mice exhibit a deficit
in non-selective and selective attentional function in the
absence of hyperactivity [87], a phenotype that is asso-
ciated with reduced striatal dopamine levels; both the
behavioural and neurochemical phenotypes could be
ameliorated by the administration of methylphenidate, a
dopamine reuptake inhibitor used therapeutically in
ADHD cases. Consistent with this, NF1-deficient mice
perform poorly on spatial and learning tasks that are
dependent upon dopaminergic function, and neural pro-
genitor cells from NF1 patients exhibit reduced dopa-
mine levels [88]. In terms of molecular pathways, the
altered gene expression profile exhibited in the hippo-
campus of heterozygous NF1 knockout mice has impli-
cated aberrant interactions between neurofibromin, the
amyloid precursor protein and the dopamine receptor
Drd3 as being important in NF1 psychopathology
[89, 90]. Finally, a recent study has shown that pan-
neuronal knockdown of NF1 in Drosophila is asso-
ciated with locomotor hyperactivity (an ADHD-like
phenotype) that could be ameliorated by the adminis-
tration of methylphenidate [91].
Brain and behavioural phenotypes in NF1 patients
may also be influenced by altered levels of circulating
glucocorticoids. It has recently been shown that dele-
tion of the NF1 gene in the adrenal cortex increases
circulating levels of stress hormones (corticosterone/
cortisol) in mouse models and patients [92]. In indi-
viduals with ADHD alone, basal cortisol levels tend
to be equivalent to those seen in non-affected indivi-
duals [93] and therefore increased basal stress hor-
mone levels are unlikely to explain the increased
propensity to ADHD in NF1. Existing research on the
genetics, cellular biology and animal models of NS
provide compelling evidence regarding PTPN11 effects
in the central nervous system. At the cellular level,
these studies show that Shp2, encoded by the PTPN11
gene, reduces myelination of axons [94] and is asso-
ciated with deficits in long-term potentiation (LTP) and
increased excitatory synaptic function in hippocampal
neurons [95]. In the mouse brain, altered Shp2 expres-
sion results in subtle increases in neuron cell density
and number, and decreases in astrocyte cell density and
number in the hippocampus and forebrain [96]. Beha-
viour in the Shp2-deficient mouse model of NS has
been described as inattentive/hyperactive [95, 97], with
cognitive deficits in memory and learning [95].
A common pathophysiology for ADHD risk in TS
and the RASopathies?
Given the overlap in clinical and neuropsychological
features between Turner syndrome and the RASopa-
thies (notably with regard to attention deficits/ADHD
risk, spatial deficits, motor problems and dyscalculia),
is there any evidence for a shared underlying patho-
physiology? There are some emerging data from clinical
and model studies suggesting that the phenotypes of
NF1-deficient individuals may be dependent upon gen-
der, e.g. female patients are more likely to require treat-
ment for visual decline than male patients, whilst only
male NF1 knockout mice appear to show spatial lear-
ning/memory deficits, increased Ras activity and dopa-
minergic abnormalities [98]. These data imply that the
Ras pathway and pathways mediated by sex-linked gene
products might somehow interact to modulate an indi-
vidual’s eventual phenotype. However, to date, there is
little information available on whether gender is a sig-
nificant factor in the manifestation of attentional prob-
lems and ADHD in NF1 and this is an avenue that may
be useful to explore in future work. Interestingly, indi-
viduals presenting with both NF1 and Turner syndrome
have been reported, highlighting the clinical similarities
between the two conditions and the possibility of a par-
tially overlapping molecular pathology [99].
NF1 deficient patients and/or rodents show subtly al-
tered CNS neuronal morphology including shorter neu-
rite lengths, smaller growth cone areas and attenuated
survival [87], altered dendritic spine number [100] and
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increased perfusion and density of microglia in the
amygdala [101]; these measures have yet to be formally
assessed in TS and associated models. Unlike in NF1-
deficient subjects, to date, there is little evidence for al-
tered neurochemistry in TS patients or the 39,XO
mouse [26, 102]. However, this dearth of information is
likely to be due to a lack of systematic investigations in
this area rather than a definite absence of karyotype-
dependent effects. Small, but significant, changes in
GABAergic receptor gene expression have been reported
in the 39,XO whole mouse brain [103], and so, poten-
tially, GABAergic system dysfunction may partially
underlie attention deficits in both NF1 and TS.
Further clues as to the shared molecular pathology
underlying ADHD phenotypes between TS and NF1
may come from a comparison of gene expression in the
two relevant mouse models (39,XO mouse and NF1 he-
terozygous knockout mouse), or cell lines from these
mutants (see above) or patients. A comparison of whole
brain gene expression in 40,XX and 39,XO mice re-
vealed only a very small number of significantly differen-
tially expressed genes [104] including the X-inactivation
escapees Eif2s3x, Utx and Ddx3x, none of which have
previously been implicated in ADHD. To reiterate, the
relevance of the 39,XO mouse model for understanding
the molecular neuropathology of TS is debatable given
the lack of X-escapees in mice relative to humans [27].
Gene expression studies in heterozygous NF1 knockout
mice have focussed on the hippocampus (largely because
of its key role in learning, memory and spatial pro-
cesses). These analyses have highlighted effects of the
mutation on the expression of genes encoding plasticity-
related synaptic proteins [105] and kinesins [90] but
do not identify Eif2s3x, Utx or Ddx3x as differentially
expressed genes. Hence, we may have failed to detect
true brain gene expression commonalities between TS
and NF1 models (perhaps due to using whole brain
or hippocampal tissue respectively), or there truly is
little overlap on this measure between the two
models. Addressing which of these two possibilities is
correct could be done through more relevant compa-
risons e.g. comparing gene expression in matched ro-
dent brain tissues, or in induced pluripotent stem cell
(iPSC)-derived neuronal cells from individuals affected
by one or other of the two conditions.
Given the current paucity of data regarding the neu-
roanatomy of NS patients, work in model systems will
be fundamental to understanding the neural correlates
of the cognitive and attentional deficits seen in this
group. Data from genetically engineered mouse models
and hippocampal slices harbouring equivalent Ptpn11
mutations to those seen in cases of NS, have revealed
abnormal myelination patterns [94], increased baseline
excitatory synaptic function and deficits in long-term
potentiation (LTP) and spatial learning [95]; the LTP and
cognitive deficits could be normalised by administration
of lovastatin, which reduces activation of the GTPase
Ras-extracellular signal-related kinase (Erk) pathway in
the brain. Currently, neither attentional function, nor
the neurochemical basis of the cognitive deficits, have
been assessed in these promising models, so it remains
to be seen whether the genetic mutation recapitulates
the ADHD phenotypes commonly observed in NS, and,
if so, whether targeted therapeutic options may alleviate
this. A priori, one might expect to see some similar
neural phenotypes in the Ptpn11 models and the NF1
knockout model and it will be interesting to see the ex-
tent to which these overlap. In contrast, one might also
expect to find differing neural phenotypes in these
models given the opposing effect of these mutations on
neurotransmitter phenotypes. Ptpn11 mutation increases
basal excitatory synaptic transmission in hippocampal
neurons and has a role in postsynaptic glutamatergic
neurons through enhanced trafficking of AMPA receptors
and effect on LTP dependent learning and memory [95].
NF1 mutation increases inhibitory synaptic transmission
in hippocampal neurons, and has a role in presynaptic
neurons through increased GABA release [80, 81].
Conclusions
Whilst we now know that ADHD rates are elevated in
Turner syndrome and the RASopathies, we still have
very little information on ADHD subtypes and co-
morbidities in these populations, about how ADHD-
related phenotypes vary with age in these conditions,
and about their underlying psychological, neural and
molecular substrates. Therefore, more detailed clinical,
neuropsychological and neuroanatomical phenotyping
across cases and appropriate neurotypical controls
across development is required; there also should be an
emphasis on measures of brain function (e.g. EEG,
fMRI) particularly during tasks taxing ADHD-related
constructs such as alerting, orienting and executive con-
trol [106], with a view to more accurately specifying the
neural systems that are particularly perturbed in TS and
RASopathies, and identifying the extent to which the
same systems are perturbed in these conditions and idio-
pathic ADHD. Studies into rare conditions are necessa-
rily hampered by low power; hence, it will be important,
perhaps through collaboration, to assess large patient
samples from diverse geographical regions, in order to
account for factors such as age and medication history,
and to stratify samples on the basis of genotype to
enable informative and robust genotype-phenotype cor-
relations to be drawn. Such studies will not only improve
our knowledge of the specific pathophysiological me-
chanisms underlying particular phenotypes and their
Green et al. Journal of Neurodevelopmental Disorders  (2017) 9:25 Page 8 of 12
amenability to treatment, but will be of importance for
genetic counselling.
The brains of patients with TS or a RASopathy cannot
be studied intimately in vivo. Hence, useful animal and
cellular models for these conditions have been, and will
continue to be, critically important for understanding
the basis of associated cognitive deficits. There are now
a number of excellent behavioural assays available for
mice that tax processes of relevance to ADHD, many of
which are conceptually and functionally analogous to
human tasks for maximal translational value [41, 107–
109]. Hence, the parallel assessment of brain structure,
and function at various levels (e.g. electrophysiological,
neurochemical via in vivo microdialysis, or imaging via
c-fos immunohistochemistry or fMRI) during perfor-
mance of such tasks, in TS and RASopathy models will
enable high resolution of the aberrant neural circuitry
underlying any cognitive phenotype; such predictions
may then be tested experimentally through techniques
such as optogenetics or DREADDs. Further work in
iPSCs originating from TS or RASopathy patient sam-
ples, or their neuronal derivatives, will also provide clues
as to molecular processes that may underlie ADHD-
related phenotypes, and that could be followed up fur-
ther in animal models and, ultimately, patients.
Studies explicitly designed to look for commonalities
and dissociations in abnormal brain structure or mo-
lecular dysfunction across conditions and models with
ADHD-like phenotypes may also be undertaken to iden-
tify and characterise pathways that may frequently be
disturbed in ADHD. This approach has recently been
taken with regard to neuroimaging phenotypes in 26
mouse models recapitulating features of autism spectrum
conditions (including the 39,XO mouse) [110], and could
feasibly be undertaken with existing rodent models for TS,
NF1 and NS.
New insights into the molecular mechanisms predis-
posing to ADHD in TS may soon come from genome-
wide genetic screens in idiopathic ADHD. To date,
genome-wide association studies, copy number variant
studies and exome/whole genome sequencing studies in
ADHD have been limited by low power, a particular
concern where the aetiology of the disorder is thought
to be multifactorial and due to a complex mix of com-
mon and rarer variants. Moreover, these studies have
traditionally neglected the X chromosome for a variety
of reasons. With more ADHD samples now available for
genotyping, a growing recognition that the X chromo-
some is influential in neurocognitive phenotypes, and
better statistical tools for dealing with X-linked data,
X-linked genes that are robustly implicated in idio-
pathic ADHD (and therefore that may play a key role
in ADHD risk within TS) may soon be identified.
Large-scale genome-wide studies in well-characterised
ADHD samples may also potentially implicate genes
involved in the Ras signalling cascade, including those
involved in NF1 and NS; through interrogation of the
clinical phenotypes associated with each variant, a
clearer picture of how the various gene mutations
may affect cognition and behaviour could be drawn.
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